According to billionaires, Pfizer Inc. is one of the 10 best pharma stocks to buy. The company reported positive Phase 3 data for their COVID-19 vaccine, demonstrating increased neutralizing antibodies in adults 65+ and high-risk adults 18-64. Pfizer continues to advance in oncology, with successful combination therapies and a focus on expanding cancer treatments.

Pfizer Inc. aims to achieve $4.5 billion in cost savings by 2025, reinvesting in R&D for innovative therapies as patents expire. Recent licensing agreements expand access to experimental oncology therapies, boosting financial performance. While Pfizer shows promise as an investment, some believe AI stocks offer greater upside potential with lower risk.

For more investment opportunities, check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy NOW.” No promotional content, just facts and insights on the best pharma stocks and investment trends.

Read more at Yahoo Finance: Pfizer Inc. (PFE) Targets $4.5B in Cost Savings to Fuel R&D and Innovative Therapies